Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.37 |
| ▸ | FEN1 | P39748 | 2/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12350617 | 1.00 | TRPV1 (0.42) | TRPV1F10ALOX5APFEN1CHRNA7 | |
| SCHEMBL12350620 | 1.00 | TRPV1 (0.42) | TRPV1F10ALOX5APFEN1CHRNA7 | |
| SCHEMBL12350624 | 1.00 | TRPV1 (0.42) | TRPV1F10ALOX5APFEN1CHRNA7 | |
| SCHEMBL12350623 | 1.00 | TRPV1 (0.42) | TRPV1F10ALOX5APFEN1CHRNA7 | |
| SCHEMBL12350616 | 0.91 | ROCK2 (0.36) | TRPV1ALOX5APFEN1HCRTR1HCRTR2 | |
| SCHEMBL1799054 | 0.90 | TRPV1 (0.41) | TRPV1CHRNA7 | |
| SCHEMBL1794842 | 0.90 | TRPV1 (0.42) | TRPV1F10 | |
| SCHEMBL1799834 | 0.88 | BRD4 (0.42) | TRPV1 | |
| SCHEMBL1797750 | 0.88 | TRPV1 (0.52) | TRPV1F10ALOX5APFEN1CHRNA7 | |
| SCHEMBL1800621 | 0.88 | TRPV1 (0.52) | TRPV1F10ALOX5APFEN1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | TRPV1 29/4885F10 4151/4885ALOX5AP 3512/4885 |
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | TRPV1 29/4885F10 4151/4885ALOX5AP 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.